The findings surrounding human milk oligosaccharides (HMOs) open new possibilities for addressing key health challenges related to maternal and newborn care globally – challenges particularly relevant for India due to its high population density and healthcare disparities.If future therapies leveraging HMOs prove viable,they could reduce dependency on antibiotics while mitigating risks of bacterial resistance-a critical issue given India’s widespread availability of antibiotics without regulated prescription protocols.
Further exploration into non-antibiotic treatments could align with India’s ongoing efforts toward affordable healthcare innovations. though, premature experimentation or commercialization could backfire in areas with limited public health education regarding infectious diseases transmitted through untreated substances like breast milk. Continued research backed by strict safety protocols will be essential as India studies such advancements under its own medical landscape needs.